bioAffinity Secures Hong Kong Patent for Lung Cancer Diagnostic
Event summary
- bioAffinity Technologies received a Hong Kong patent (No. HK40048460) for its CyPath® Lung noninvasive lung cancer diagnostic technology.
- The patent covers the use of fluorescent markers and flow cytometry to detect lung cancer cells in sputum.
- This follows a 2025 patent grant in China, strengthening bioAffinity's IP protection in Asia.
- CyPath® Lung is marketed as a Laboratory Developed Test (LDT) with 92% sensitivity and 87% specificity in clinical trials.
The big picture
The Hong Kong patent strengthens bioAffinity's intellectual property portfolio in a region with a high burden of lung cancer. This move aligns with the broader trend of biotech companies securing international patents to protect their innovative diagnostics and expand market reach. The company's ability to navigate regulatory environments and commercialize its technology will be critical to its success.
What we're watching
- Market Expansion
- How bioAffinity will leverage this patent to penetrate the Asian market, where lung cancer cases are high.
- Regulatory Hurdles
- Whether the company can secure similar patents in other key markets to solidify its global position.
- Commercialization Pace
- The speed at which bioAffinity can commercialize CyPath® Lung in Hong Kong and other regions.
Related topics